Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Graft Polymer (UK) PLC ( (GB:SVNS) ) has issued an announcement.
Solvonis Therapeutics plc has initiated key translational studies for its sublingual esketamine oral thin film candidate, SVN-002, aimed at treating moderate-to-severe Alcohol Use Disorder (AUD) in the US. This step is part of their strategy to advance SVN-002 towards a Phase 2b clinical trial, leveraging the FDA’s 505(b)(2) regulatory pathway for a potentially accelerated approval process. The company has partnered with WuXi AppTec to conduct a pharmacokinetic program to generate necessary scientific data, marking a critical milestone in their development timeline. This initiative underscores Solvonis’ commitment to addressing the underserved AUD market, which affects approximately 29 million individuals in the US.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company based in London and listed on the London Stock Exchange. The company focuses on developing novel medicines for addiction and mental health disorders, targeting high-burden neuropsychiatric conditions with significant unmet needs. Its lead programs address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with a pipeline that includes repurposed and novel compounds. Solvonis is advancing an AI-supported discovery platform and has a capital-efficient model aimed at innovation in neuropsychiatry.
Average Trading Volume: 85,006,480
Technical Sentiment Signal: Buy
Current Market Cap: £19.66M
For a thorough assessment of SVNS stock, go to TipRanks’ Stock Analysis page.